SCHEMBL26326653

SCHEMBL26326653

CC(O)(CCc1ccccc1)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.46
CHRM2 P08172 4/20 0.46
CHRM1 P11229 4/20 0.46
KCNH2 Q12809 3/20 0.46
SLC18A3 Q16572 2/20 0.44
CHRM3 P20309 6/20 0.43
CHRM4 P08173 2/20 0.43
CHRM5 P08912 2/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
HRH1 P35367 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933428 0.82 CHRM3 (0.45) CYP2D6CHRM2CHRM1KCNH2SLC18A3
SCHEMBL25971519 0.82 SLC6A2 (0.44) CYP2D6CHRM2CHRM1KCNH2SLC18A3
SCHEMBL27997622 0.82 CHRM3 (0.47) CYP2D6CHRM2CHRM1KCNH2SLC18A3
SCHEMBL2791594 0.77 L3MBTL1 (0.48) CYP2D6CHRM2CHRM1KCNH2CHRM3
SCHEMBL4278250 0.76 L3MBTL1 (0.45) CHRM3L3MBTL1TSHRTAAR1
SCHEMBL4429328 0.76 CHRM2 (0.50) CYP2D6CHRM2CHRM1KCNH2SLC18A3
SCHEMBL1357618 0.75 CHRM2 (0.41) CYP2D6CHRM2CHRM1KCNH2SLC18A3
SCHEMBL25043591 0.74 SLC6A2 (0.47) CYP2D6CYP3A4TDP1TAAR1MAPT
SCHEMBL15314328 0.73 LTB4R (0.51) SLC18A3GRIN1GRIN2BL3MBTL1TAAR1
SCHEMBL272368 0.73 TDP1 (0.48) L3MBTL1TDP1TAAR1MAPTKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE HPD, TALDO1, OGG1 CYP2D6 315/4885CHRM2 4565/4885CHRM1 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.